Maarten Cozijnsen

38 Table 1. Basic characteristics of the derivation and validation cohorts (mean±SD, median (IQR) and percentage displayed as appropriate) Derivation cohort (n=154) Validation cohort 1 (n=86) Females (%) 42% 44% Age (years) 14.1±2.5 15.4±2.5 Disease-duration (years) 2.2 (0.3-4.3) 1.5 (1.1-3.4) Albumin (g/dL) 4.0±0.6 4.5±0.3 ESR (mm/hr) 18 (10-35) 10 (4-21) CRP (mg/L) 6.2 (1.8-20.5) 0.4 (0.3-0.9) FC (μg/g) 632 (163-1287) 107 (34-711) 1 FC<300μg/g 31% 62% wPCDAI Remission (PCDAI<10 / wPCDAI<12.5) 33% 88% Mild (PCDAI 10-27.5 / wPCDAI 12.5-40) 47% 7% Moderate to severe (PCDAI≥30 / wPCDAI>40) 20% 5% SESCD score 9 (4-15) 1 (0-3) Remission (<3) 16% 65% Mild (3-9) 36% 23% Moderate-to-severe (>9) 49% 11% 1 In the validation cohort, FC results are capped at 2000μg/g. Validation cohort 1=prospective cohort South Korea; Validation cohort 2= Bio-bank registry Shaare Zedek Medical Center; Validation cohort 3= multicenter RCT TISKids ESR=erythrocytes sedimentation rate; CRP=C-reactive protein; FC=fecal calprotectin; PCDAI=pediatric Crohn’s disease activity index; SESCD=simple endoscopic score for Crohn’s disease; MRE=magnetic resonance enterography; NA=not available.